Last edition
News about "LYMPHIR"
Citius Oncology reports positive Phase I data showing encouraging safety and response rates for LYMPHIR combined with Keytruda in recurrent gynecologic cancers, supporting further Phase II evaluation.
LYMPHIR | 11/03/2026 | By News Bureau | 109
Citius Pharma Subsidiary Acquires TenX Keane to Establish Citius Oncology
Citius Pharmaceuticals, Inc. has completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition (TenX).
LYMPHIR | 14/08/2024 | By Aishwarya | 608
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy